Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

[Rare breast tumors].

Annales de chirurgie plastique et esthetique·2025
Same author

Radiation-associated angiosarcoma of the breast: consider chemotherapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

ESMO open·2025
Same author

Editorial Expression of Concern: Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.

Oncogene·2025

Related Experiment Video

Updated: Mar 26, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

844

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between

D Mouttet1, M Laé2, M Caly2

  • 1Department of Surgery, Institut Curie, Paris, France.

Plos One
|February 2, 2016
PubMed
Summary

The MapQuant™ genomic assay shows high concordance with standard immunohistochemistry for Estrogen Receptor and HER2 status in early-stage breast cancer, offering a more objective assessment than routine IHC. This genomic test provides reliable results for hormone receptor and HER2 status.

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 26, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

844
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Hormone receptor (estrogen receptor, progesterone receptor) and HER2 status are critical for breast cancer prognosis.
  • Immunohistochemistry (IHC) is the standard method for assessing these biomarkers but suffers from variability.
  • Objective assessment of these markers is needed to improve treatment decisions.

Purpose of the Study:

  • To compare the accuracy of the MapQuant™ genomic assay with routine IHC for ER, PR, and HER2 status.
  • To evaluate the concordance and reliability of the MapQuant™ test in early-stage invasive breast cancer.

Main Methods:

  • Retrospective analysis of 163 early-stage invasive breast cancer cases.
  • Comparison of MapQuant™ genomic assay results with standard IHC results.
  • Statistical analysis including concordance rates and Cohen's Kappa coefficients.

Main Results:

  • High concordance (97.5%, Kappa=0.89) between MapQuant™ and IHC for Estrogen Receptor (ER) status.
  • Moderate concordance (91.4%, Kappa=0.74) for Progesterone Receptor (PR) status.
  • Excellent concordance (99.3%, Kappa=0.86) for HER2 status, with only 1.2% undetermined results.

Conclusions:

  • The MapQuant™ assay provides an objective and quantitative assessment of ER, PR, and HER2 status in invasive breast cancer.
  • Genomic assessment via MapQuant™ offers a reliable alternative to IHC, potentially reducing variability.
  • This assay can aid in more accurate prognostic determination and treatment planning for breast cancer patients.